Malwina Maliszewska: Advancing Coagulation Diagnostics at ISTH 2026
Malwina Maliszewska, CC and Hemostasis Product Specialist at HORIBA Medical, shared a post on LinkedIn:
“Three extremely inspiring days during the ISTH 2026 conference in Paris are behind us!
This unique event is a great opportunity to learn about the latest developments in the field of haemostasis and thrombosis, exchange experiences with experts from all over the world and establish many valuable contacts.
I am particularly pleased that together with Zuzanna Cichoszewska and Gabriela Górska-Wielgosz we were able to present our work during a poster session:
Analytical agreement of INR between two tissue thromboplastins with different ISI using a nephelometric PT method on a single coagulation platform, which I co-authored.
The opportunity to present research results at such a prestigious, international forum is a great distinction and motivation for further development.
I would like to thank all the co-authors and Bruno Pougault for their cooperation and the opportunity to implement this project.
Participation in the ISTH congress was a great experience and an opportunity to learn about the latest developments in the diagnosis of hemostasis disorders.”
Stay updated with Hemostasis Today.
-
Jul 14, 2026, 11:07Mary Cushman: Honoring Outstanding Mentorship at ISTH 2026
-
Jul 14, 2026, 10:53Maha Othman: Advancing the Management of Inherited Thrombocytopenias at ISTH 2026
-
Jul 14, 2026, 10:24Sara Zalghout: The Little Things That Make ISTH 2026 Special
-
Jul 14, 2026, 10:11Joseph R. Shaw: GAUGE Advances FXa Inhibitor Reversal at ISTH 2026
-
Jul 13, 2026, 23:39Yaariv Khaykin: Whole-Person Care Can Strengthen Stroke Prevention in Patients With Atrial Fibrillation
-
Jul 13, 2026, 22:33ESOC 2026 recordings are now available on eSTEP – European Stroke Organisation
-
Jul 13, 2026, 20:17Julia R. Coleman: Fantastic First Day at ISTH 2026
-
Jul 13, 2026, 20:11Ruah Alyamany: Combination Therapy Improves Quality of Life in ITP
-
Jul 13, 2026, 19:47Brian O Mahony: Two-Year Results of BBM-H901 Gene Therapy Presented at ISTH 2026